Qnexa
[kyoo-nek-suh] is an investigational drug candidate being developed to
address weight loss, type 2 diabetes and obstructive sleep apnea. Qnexa
is a once-a-day, proprietary, oral, controlled-release formulation of
low-dose phentermine and topiramate, which is designed to decrease
appetite and increase satiety (the sense of feeling full), the two main
mechanisms that impact eating behavior. In Phase 2 and Phase 3 clinical
data to date, patients taking Qnexa have demonstrated statistically
significant weight loss, better glycemic control, and improvement in
cardiovascular risk factors when they used the drug in combination with a
diet and lifestyle modification program.
On February 22, 2012, the United States Food and Drug Administration Endocrinologic and Metabolic Drugs Advisory Committee recommended, in a 20-to-2 vote, that Qnexa be granted marketing approval for the treatment of obesity in adults. The Prescription Drug User Fee Act target date for Qnexa is July 17, 2012.
On February 22, 2012, the United States Food and Drug Administration Endocrinologic and Metabolic Drugs Advisory Committee recommended, in a 20-to-2 vote, that Qnexa be granted marketing approval for the treatment of obesity in adults. The Prescription Drug User Fee Act target date for Qnexa is July 17, 2012.
Dadecated link for Go Daddy.com Just ez2.me
Remember nick name for Godaddy.com www.ez2.me Tell your friends about Easy To Me, Go Daddy,s Approved affiliate
No comments:
Post a Comment